CytoDyn (OTC: CYDY) Releases Mechanism of Action Animation for Leronlimab in Immuno-Oncology
VANCOUVER, Washington, July 02, 2020 — CytoDyn Inc. (CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the public […]
